Literature DB >> 30972662

Predictors of amyotrophic lateral sclerosis mimic syndrome.

Cecilia Quarracino1, María Constanza Segamarchi2, Gabriel E Rodríguez3.   

Abstract

The term amyotrophic lateral sclerosis mimic syndrome (ALSms) includes pathologies that present signs or symptoms similar to those caused by amyotrophic lateral sclerosis (ALS), which can lead to misdiagnosis. In general, any kind of misdiagnosis can result in negative clinical, psychological and economic consequences as well diagnostic and treatment delay. The objectives were to determine the frequency and to compare the demographic and clinical characteristics of patients with ALS and ALSms in our ALS clinic. We retrospectively studied all patients evaluated from 2007 to 2017 including only patients with a definite final diagnosis. Out of 368 patients with motor neuron disease symptomatology, 43 (11.7%) had an ALSms. The most frequent etiology was compressive myelopathy (32.6%). Multivariate analysis considering positive associations was statistically significant for patients having only upper or lower motor neuron signs in the physical examination, a non-compatible electromyogram (EMG), as well as atypical first symptoms. ALS misdiagnosis is an ongoing and not infrequent problem. From our series of patients, atypical symptoms, absence of EMG pathological findings or isolated upper or lower motor neuron disease should prompt suspicion of a differential diagnosis.

Entities:  

Keywords:  ALS differential diagnosis; ALS mimic disorder; ALS mimic syndrome; Spondylotic myelopathy

Year:  2019        PMID: 30972662     DOI: 10.1007/s13760-019-01135-1

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  2 in total

1.  ALS Mimics due to Affection of the Cervical Spine: From Common Compressive Myelopathy to Rare CSF Epidural Collection.

Authors:  Benedetta Storti; Susanna Diamanti; Lucio Tremolizzo; Nilo Riva; Christian Lunetta; Massimo Filippi; Carlo Ferrarese; Ildebrando Appollonio
Journal:  Case Rep Neurol       Date:  2021-03-04

2.  Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina.

Authors:  C Quarracino; M Bendersky; R Rey; G E Rodríguez
Journal:  Acta Neurol Belg       Date:  2020-05-20       Impact factor: 2.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.